Predisposing Gene Associated With Cowden Syndrome
By LabMedica International staff writers Posted on 15 Nov 2015 |
Image: Mucocutaneous papilloma manifestations around the nose of an autosomal dominant condition known as Cowden syndrome (Photo courtesy of University of Sao Paulo).
A new gene has been discovered that is associated with Cowden syndrome, an inherited condition that carries high risks of thyroid, breast, and other cancers, and a subset of non-inherited thyroid cancers.
Cowden syndrome (CS) is an underdiagnosed difficult-to-recognize autosomal-dominant disorder characterized by multiple hamartomas and an increased predisposition to breast, thyroid, endometrial, and other cancers and other non-neoplastic phenotypes that include macrocephaly and mucocutaneous findings.
Scientists at the Cleveland Clinic (Cleveland, OH, USA) and their colleagues subjected germline genomic DNA extracted from peripheral-blood leukocytes of the eligible proband to exome sequencing. Exome enrichment was performed, and subsequent 100 bp paired-end sequencing was performed with a HiSeq 2000 platform (Illumina, San Diego, CA, USA). Mutations in candidate genes of interest were validated by polymerase chain reaction (PCR)-based region-specific mutation analysis through Sanger sequencing. Sequencing was performed in the forward and reverse directions with ABI 3730xl DNA Analyzers (Applied Biosystems, Foster City, CA, USA).
Exome sequencing and targeted genotyping identified Sec23 homolog B, COPII coat complex component (SEC23B) as a candidate gene in a CS-affected family with predominant thyroid cancer. Further analyses uncovered that SEC23B mutations are present in up to 3% of unrelated Cowden syndrome patients and in 4% of patients with non-syndromic thyroid cancer. With up to 50% of Cowden syndrome patients testing negative for all known genetic mutations, the syndrome remains an under-diagnosed and difficult-to-recognize condition.
Patients with Cowden syndrome develop noncancerous growths, called hamartomas that can appear on the skin in mucous membranes and in the intestinal tract. Cowden syndrome predisposes individuals to several types of cancers, an 85% lifetime risk of breast cancer, a 35% risk for epithelial thyroid cancer, and increased risks of uterine, kidney and colon cancers as well. At least one in 200,000 people are affected by the disease.
Charis Eng, MD, PhD, the senior author of the study said, “This isn't the first time we discovered novel genetic mutations in Cowden syndrome, but what was truly remarkable is that the SEC23B gene had been identified back in 2009 as the cause of a very rare type of anemia, but not cancer. Our data not only identified a novel cancer-predisposing gene, particularly in thyroid cancer, but also highlighted how cellular stress responses can be hijacked by cancer cells to promote their survival.” The study was published on October 29, 2105 in the American Journal of Human Genetics.
Related Links:
Cleveland Clinic
Illumina
Applied Biosystems
Cowden syndrome (CS) is an underdiagnosed difficult-to-recognize autosomal-dominant disorder characterized by multiple hamartomas and an increased predisposition to breast, thyroid, endometrial, and other cancers and other non-neoplastic phenotypes that include macrocephaly and mucocutaneous findings.
Scientists at the Cleveland Clinic (Cleveland, OH, USA) and their colleagues subjected germline genomic DNA extracted from peripheral-blood leukocytes of the eligible proband to exome sequencing. Exome enrichment was performed, and subsequent 100 bp paired-end sequencing was performed with a HiSeq 2000 platform (Illumina, San Diego, CA, USA). Mutations in candidate genes of interest were validated by polymerase chain reaction (PCR)-based region-specific mutation analysis through Sanger sequencing. Sequencing was performed in the forward and reverse directions with ABI 3730xl DNA Analyzers (Applied Biosystems, Foster City, CA, USA).
Exome sequencing and targeted genotyping identified Sec23 homolog B, COPII coat complex component (SEC23B) as a candidate gene in a CS-affected family with predominant thyroid cancer. Further analyses uncovered that SEC23B mutations are present in up to 3% of unrelated Cowden syndrome patients and in 4% of patients with non-syndromic thyroid cancer. With up to 50% of Cowden syndrome patients testing negative for all known genetic mutations, the syndrome remains an under-diagnosed and difficult-to-recognize condition.
Patients with Cowden syndrome develop noncancerous growths, called hamartomas that can appear on the skin in mucous membranes and in the intestinal tract. Cowden syndrome predisposes individuals to several types of cancers, an 85% lifetime risk of breast cancer, a 35% risk for epithelial thyroid cancer, and increased risks of uterine, kidney and colon cancers as well. At least one in 200,000 people are affected by the disease.
Charis Eng, MD, PhD, the senior author of the study said, “This isn't the first time we discovered novel genetic mutations in Cowden syndrome, but what was truly remarkable is that the SEC23B gene had been identified back in 2009 as the cause of a very rare type of anemia, but not cancer. Our data not only identified a novel cancer-predisposing gene, particularly in thyroid cancer, but also highlighted how cellular stress responses can be hijacked by cancer cells to promote their survival.” The study was published on October 29, 2105 in the American Journal of Human Genetics.
Related Links:
Cleveland Clinic
Illumina
Applied Biosystems
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans